High-risk human papillomaviruses (HPVs) are etiologically linked to human cervical and oral cancers. The E6 and E7 oncoproteins encoded by HPV target host cell tumor suppressor proteins. E6 induces proteolysis of p53 through the ubiquitin-proteasome pathway. Recent studies showed that overexpression of E7 caused proteolytic degradation of the tumor suppressor Rb. However, unlike p53, Rb is not regulated by proteolysis in normal cells. In addition, it was unclear whether in its natural context E7 regulates Rb through the ubiquitinproteasome pathway. Therefore, we sought to determine whether Rb is regulated by the ubiquitin-proteasome pathway in HPV-containing tumor cells. We carried out a detailed analysis in Caski cells, that are derived from HPV-containing cervical cancer tissues. Studies with various protease inhibitors revealed that Rb is regulated speci®cally by the ubiquitin-proteasome pathway in HPV-containing cervical tumor cells. Several inhibitors of the 26S proteasome signi®cantly increased the level of Rb in the Caski cells. Rb controls cell growth by forming complexes with the E2F-family transcription factors. Surprisingly, in spite of a signi®cant accumulation of the hypophosphorylated form of Rb, no Rb/E2F complex was detectable in the proteasome inhibitor treated cells. Further analysis revealed that there was an increased accumulation of the E7 oncoprotein. We showed that the proteasome inhibitors simultaneously blocked the proteolysis of E7 and Rb, suggesting that E7 is also regulated by the ubiquitin-dependent proteolysis in cervical cancer cells. Taken together, this study suggests that targeted inhibition of Rb proteolysis will be required for restoring Rb function in HPV-containing cervical cancer cells. Oncogene (2001) 20, 4740 ± 4749.
Introduction
Human papillomaviruses (HPV) are etiologically linked to more than 90% of cervical cancers (reviewed in Howley, 1996; zur Hausen, 1999 ) and 20 ± 30% of oral and head and neck cancers (Key et al., 1999; Niv et al., 2000) . All HPV-transformed cancer tissues express two HPV-encoded oncoproteins, E6 and E7. Both E6 and E7 possess transformation activity, and they cooperate to transform primary human keratinocytes, ®broblasts, and epithelial cells (reviewed in Vousden, 1995; Galloway and McDougall, 1996; Jones and Munger, 1996) . The transforming activity of E7 is associated with its ability to interact with the retinoblastoma tumor suppressor protein, Rb (Halbert et al., 1992; Hecks et al., 1992) . The E7 proteins encoded by the high-risk type HPVs, such as HPV16 and HPV18, bind Rb with a much higher anity compared to those encoded by the low-risk type HPVs, such as HPV6 and HPV11. E7 binds to a region of the Rb protein commonly referred to as the`pocket domains' (reviewed in Jones and Munger, 1996) . The`pocket domain' sequences of Rb are essential for its tumor suppressor function and many naturally occurring loss-of-function mutations of Rb appear to cluster in these`pocket domains'. One of the major biochemical functions of Rb is to bind the E2F-family transcription factors and repress expression of the replication enzyme genes (reviewed in Nevins, 1998; Lipinski and Jacks, 1999) . The ability to repress expression of the replication enzyme genes correlates with the tumor suppression function of Rb (Lipinski and Jacks, 1999; Nevins, 1998) . E7 disrupts the interaction between Rb and E2F, resulting in a release of the E2F factors in their transcriptionally active forms (Chellapan et al., 1992; Pagano et al., 1992) . This E7-mediated conversion of E2Fs to their activator forms stimulates DNA replication and cell-division, which is consistent with the observation that keratinocytes constitutively expressing E7 remain replication-competent even after dierentiation (Cheng et al., 1995) .
The E6 oncoprotein of human papillomaviruses inactivates the cellular tumor suppressor protein p53 by binding and targeting it for degradation (Howley, 1996; Schener et al., 1990) . Both in non-HPV and HPV-transformed cells, p53 degradation occurs through the ubiquitin-26S proteasome (Maki et al., 1996) . In HPV-transformed cells, E6 binds to p53 and to an E6-binding protein E6AP (a ubiquitin ligase) that leads to polyubiquitination of p53 (Huibregtse et al., 1991; Schener et al., 1993) . In non-HPV cells, Mdm2 functions as the ubiquitin ligase for ubiquitination of p53 (Fang et al., 2000; Honda and Yasuda, 1999) . Recent studies in our laboratory and by two other research groups showed that E7 also induces a proteolytic degradation of Rb (Boyer et al., 1996; Jones and Munger, 1997; Berezutskaya et al., 1997b) . Using recombinant adenovirus expressing the HPV16 E7 protein, we showed that the expression of E7 increases the rate of decay of the Rb protein (Berezutskaya et al., 1997b) . Other studies have also shown that the half-life of the Rb protein is reduced in cells stably transformed with E7 (Boyer et al., 1996; Jones and Munger, 1997) . Our results as well as studies by Boyer et al. (1996) showed that the E7 induces degradation of Rb through the 26S proteasome (Berezutskaya et al., 1997b) .
The E7-induced proteolysis of Rb is distinct from the E6-induced proteolysis of p53 in that Rb is not known to be regulated by ubiquitin-dependent proteolysis in normal cells. Therefore, we sought to determine whether Rb is indeed regulated by proteolysis in the physiological context of papillomavirus infection. In this study, we show that the cellular level of Rb is regulated by ubiquitin dependent proteolysis in HPVcontaining cervical cancer cells. High levels of hypophosphorylated Rb accumulate when the HPV transformed Caski cells were treated with the proteasome inhibitor MG132. However, the no Rb/E2F complexes were formed in MG132 treated Caski cells. Further analysis revealed that the E7 protein is also regulated by the ubiquitin-proteasome pathway. High levels of E7 accumulate in proteasome inhibitor treated Caski cells. Furthermore, using transient transfection assays in C33A cells, we provide evidence that E7 can promote ubiquitination of Rb. Both polyubiquitinated Rb and E7 were detected in MG132 treated Caski cells. Results presented in this study show that, although proteasome inhibitors allow accumulation of growth suppressing form of Rb in cervical carcinoma cells, Rb function is not restored in these cancer cells.
Results

The proteasome inhibitors specifically increase the level of cellular Rb in HPV-transformed Caski cervical carcinoma cells
Previous studies have demonstrated that acute overexpression of E7 either by retroviral or adenoviral vectors can induce proteasomal degradation of Rb in keratinocytes and breast epithelial cells (Berezutskaya et al., 1997b; Boyer et al., 1996; Jones et al., 1997) . However, these studies did not address whether in its natural context E7 causes proteolysis of Rb. To investigate whether Rb is targeted for proteasomal degradation in HPV-containing cervical cancer cells, we treated Caski cells (HPV-transformed) with dierent cell-permeable protease inhibitors for 4 h, and the cell lysates were analysed for the steady-state level of cellular Rb using the Western blot assay. The proteasome inhibitors, MG132, PSI and lactacystin markedly increased the level of cellular Rb protein in Caski cells (Figure 1a , lanes 5 ± 7). In contrast, dimethyl sulfoxide (DMSO) (Figure 1a , lane 2), the cysteine protease inhibitor E64 (lane 4), caspase-1 inhibitor I (lane 8), caspase-3 inhibitor I (lane 9), and the protease inhibitor leupeptine (lane 3) did not signi®cantly change the level of cellular Rb. p53 is a known target of the 26S proteasome in the HPVtransformed cells, and the proteasome inhibitor treated Caski cell extracts showed signi®cant accumulation of p53 ( Figure 1b , lanes 5 ± 7). These results show that Rb is proteolysed by the 26S proteasome in the HPVcontaining cervical carcinoma cells (Figure 1a) . Caski cells were treated with dierent protease inhibitors, leupeptin (2 mM), E64 (10 mM), MG132 (10 mM), PSI (50 mM), lactacystin (10 mM), caspase-l inhibitor-I (100 mM), and caspase-3 inhibitor-I (100 mM) for 4 h. Three hundred micrograms of cell lysates were analysed for the Rb protein by the Western blot assay. (b) One hundred micrograms of the same cell lysates were analysed for the p53 protein by the Western blot assay. (c) Two hundred micrograms cell lysates from the untreated, DMSO-treated and MG132 (10 mM)-treated Caski cell lysates were separated by SDSpolyacrylamide (7%) gel electrophoresis and immunoblotted using the Rb, p107, or the p130 antibody E7 binds to two other Rb-family proteins, p107 and p130 (reviewed in Vousden, 1995; Galloway and McDougall, 1996) . We analysed the steady-state levels of these two Rb-family proteins in the DMSO treated and the MG132 treated Caski cells by immunoblot assays. No signi®cant change in either of these proteins was observed (Figure 1c) , suggesting that among the Rb-family proteins, only Rb is a major target for proteasomal degradation in the HPV-containing Caski cells. This result is consistent with our previous ®nding that E7 speci®cally degrades the Rb protein (Berezutskaya et al., 1997b) .
Hypophosphorylated Rb is accumulated in MG132 treated Caski cells
Using the proteasome inhibitor MG132, we analysed the level and the kinetics of accumulation of Rb in Caski cells. A dosage-dependent increase in the steadystate level of the Rb protein was observed, and treatment with 2.5 mM MG132 led to maximum accumulation of Rb (Figure 2a) . Within 1 h of MG132 treatment, a faster migrating form of Rb started to accumulate, and maximum accumulation of Rb was observed after 4 ± 5 h of treatment (Figure 2b ). The Rb protein that accumulated in MG132 treated Caski cells migrated faster than the phosphorylated Rb in an SDS-polyacrylamide gel. To determine the phosphorylation status of this Rb, the MG132 treated and untreated extracts were probed with the Rbantibody (G99-549) that speci®cally recognizes the hypophosphorylated form of Rb. As can be seen in Figure 2c , the majority of Rb accumulating in MG132 treated Caski cell extract corresponded to the hypophosphorylated form of Rb.
E2F/Rb complexes are not detectable in proteasome inhibitor (MG132) treated Caski cells
Hypophosphorylated form of Rb associates with the E2F-family transcription factors (E2Fs) to repress the expression of the replication enzyme genes. Previous studies have shown that Caski cells predominantly contain free E2Fs (Chellapan et al., 1992) . Since we observed signi®cant accumulation of hypophosphorylated Rb in proteasome inhibitor treated Caski cells, the cell lysates were also analysed for the E2F/Rb complexes. Antibodies against various members of E2F and DP family proteins in supershift assays revealed that the majority of the E2F DNA-binding activities consisted of E2F-4/DP1 heterodimers ( Figure 3 ). Actively dividing Caski cells were treated with DMSO or MG132 (10 mM) for 1 ± 5 h and 300 mg of cell lysates were resolved by SDS-polyacrylamide (8%) gel electrophoresis and analysed for the Rb protein by Western blot assay. (c) Caski cells were treated with DMSO or MG132 (10 mM) for 5 h and 200 mg of cell lysate was resolved by SDSpolyacrylamide (7%) gel electrophoresis and analysed for Rb protein by Western blot assay using the Rb antibody G3-245 that recognizes both hypo and hyperphosphorylated Rb. Three hundred and ®fty micrograms proteins of the same extracts was probed with the Rb-antibody G99-549 that recognizes speci®cally the unphosphorylated Rb cells did not reveal any signi®cant dierence in the E2F-complexes ( Figure 3b ). We did not detect any slower migrating Rb/E2F complex in the MG132-treated or untreated Caski cell extracts ( Figure 3b ). Addition of Rb-antibodies that supershift the Rb-E2F complex, did not have any eect on the E2F-complexes ( Figure 3b ). It is known that E7 prevents formation of the Rb/E2F complexes (Chellapan et al., 1992; Pagano et al., 1992) . Therefore, the lack of E2F/Rb complex in MG132 treated Caski cells prompted us to compare the levels of the E7 protein in MG132 treated and untreated cells. A dosage-dependent increase in the level of the E7 protein was readily observed after treatment with dierent concentrations of MG132 for 4 h (Figure 3c ). This result shows that E7 is also degraded via the ubiquitin proteasome pathway and the proteasome inhibitor MG132 simultaneously increases the level of Rb and E7 in Caski cells. It also suggests that the higher level of E7 prevented the formation of E2F/Rb complex in MG132 treated Caski cells.
Comparison of DMSO-treated and the MG132-treated
To obtain further evidence that the lack of E2F/Rb complex in MG132 treated Caski cells was due to an increase in the level of E7, we carried out an experiment with actinomycin D. Actinomycin D inhibits mRNA synthesis and it has been shown that treatment of Caski cells with low level of actinomycin D leads to a depletion of E7 mRNA (Hietanen et al., 2000) . Therefore, we predicted that actinomycin D treatment would deplete E7 protein and cause an accumulation of E2F/Rb complex. Consistent with this notion, when the Caski cells were treated with low levels of actinomycin-D (2.4 nM), a dramatic change in the E2F-complexes was observed (Figure 4) . In actinomycin-D treated cells, the overall E2F-binding activity was signi®cantly decreased, but a new E2F/ DNA complex was detected (Figure 4, lane 1) . Supershift experiments with two Rb-antibodies and a p130 antibody showed that the newly formed E2F-complex is the Rb/E2F complex. Two Rb antibodies independently supershifted the complex, whereas a p130 antibody showed no eect on the complex (Figure 4a ). A comparison of the level of E7 between untreated and the actinomycin-D treated Caski cells showed that the E7 protein was dramatically decreased in actinomycin-D treated cells (Figure 4b ).
Both Rb and E7 are ubiquitinated in HPV-transformed cervical carcinoma cells
Although past studies have implicated the 26S proteasome in E7-induced proteolysis of Rb, ubiqui- Caski cells were treated with MG132 (0.25 ± 50 mM) and 10 mg of the cell extracts were analysed by gel retardation assay using 32 P-labeled oligonucleotides containing E2F-binding site as a probe. Ten micrograms of 50 mM MG132 treated Caski cells were incubated with 1 ml of either Rb-antibody (C-18) or Rb-antibody (G3-245) antibody prior to gel retardation assay. (c) E7 is proteolysed by the 26S proteasome in HPV containing cervical carcinoma cells. Caski cells were treated with DMSO or increasing concentration of MG132 (0.25 ± 50 mM) for 4 h and 300 mg of cell extracts were resolved on a 12% polyacrylamide-SDS gel and analysed for the E7 protein by using Western blot assay tin-Rb conjugates have not been demonstrated. To detect the ubiquitinated Rb proteins, the cell lysates from the DMSO-treated and the MG132-treated Caski cells were immunoprecipitated with monoclonal Rbantibody (Ab-1), the immunoprecipitated proteins were resolved by SDS ± PAGE and immunoblotted with a monoclonal antibody against ubiquitin. A series of slower migrating bands ranging in molecular weights from 115 kD to 250 kD were detected by the ubiquitin antibody in the Rb immunoprecipitates from the MG132-treated Caski cell lysates (Figure 5a, lane 2) . These bands were not detected in the Rb immunoprecipitates from the DMSO treated Caski cell lysates (Figure 5a, lane 1) . These high molecular weight bands represent polyubiquitinated Rb and this result provides evidence for ubiquitination of Rb in Caski cervical carcinoma cells. The lack of ubiquitinated Rb in the DMSO-treated Caski cells suggests that the ubiquitinated Rb is highly labile in the Caski cells.
To detect the ubiquitinated E7 protein, we immunoprecipitated the Caski cell lysates in denaturing SDS-containing buer (to prevent co-precipitation of E7/polyubiquitin Rb complexes) with agarose conjugated E7 monoclonal antibody. The immunoprecipitated proteins were then immunoblotted with the monoclonal ubiquitin antibody. A smear of high molecular weight protein bands was detected in the E7-immunoprecipitates by the monoclonal ubiquitin antibody ( Figure 5b, lane 2) . These bands represent polyubiquitinated E7 proteins, con®rming that E7 is eciently ubiquitinated in Caski cells.
Rb-proteolysis correlates with E7-binding
Experiments described above show that E7 induces proteolysis of Rb through the ubiquitin ± proteasome pathway and the E7 protein is also ubiquitinated and degraded by the 26S proteasome in HPV-transformed Caski cells. To investigate whether the Rb-proteolysis is a direct consequence of binding to E7, we analysed the eects of mutants E7 proteins, which cannot bind to Rb. First, we transfected the non-HPV cervical carcinoma C33A cells with the HPV16 E7 expression plasmid with increasing levels of the proteasome inhibitors and the results presented in Figure 6a showed a dosage-dependent increase in the level of the E7 protein in MG132-treated C33A cell extracts. C33A cells were then transfected with plasmids expressing Rb (379 ± 928) and the wild-type or mutant E7. Consistent with the previous ®nding, transfections of the wild-type E7 induces proteolytic degradation of Rb in C33A cells (Figure 6b , lane 2). Previous studies showed that E7 mutants C24-S and E26-Q cannot bind Rb. Transfections of these mutants did not induce proteolysis of Rb in C33A cells (Figure 6c ). The proteasome inhibitor MG132 eciently blocked the degradation of both Rb and E7 in transfected cells (Figure 6b, lane 3) . However, the MG132 treatment showed no signi®cant eect on the level of Rb cotransfected with two E7-mutants (Figure 6d ). These results are consistent with the notion that the direct interaction between Rb and E7 is critical for the proteolysis of Rb.
HPV16 E7 promotes ubiquitination of Rb
Proteasomal degradation of proteins involves two major steps: (1) polyubiquitination of the target protein; and (2) recognition and degradation of the ubiquitinated protein by the 26S proteasome (reviewed in King et al., 1996) . To analyse the role of E7 in Rb ubiquitination, we performed transient transfection assays using the C33A cells. For detection of the in vivo ubiquitinated Rb in the transfected cells, we used the V5-epitope tagged Rb (V5-Rb) and histidine-tagged ubiquitin (His-Ub). C33A cells were cotransfected with the expression plasmids of V5-Rb and His-Ub both in the presence and absence of E7 expression plasmid. The transfected cells were also treated for 4 h with 10 mM MG132 to prevent proteolysis of the ubiquitinated Rb. The Rb in the transfected cell lysates was immunoprecipitated using the V5-antibody and protein G sepharose. The immunoprecipitates were then separated on a SDS-polyacrylamide gel and were subjected to immunoblot analysis using an antibody speci®c for the His-epitope. Multi-ubiquitinated forms of V5-tagged Rb were seen only in the MG132-treated cells transfected with E7, V5-Rb, and His-Ub expressing plasmids (Figure 7, lane 3) . In cells transfected 
Discussion
The current study is signi®cant in several ways. First, using the Caski cells, we showed that the retinoblastoma tumor suppressor protein Rb is degraded by ubiquitin dependent proteolysis in HPV-containing cervical carcinoma cells. Proteasome inhibitors led to accumulation of high levels of hypophosphorylated Rb, however no E2F/Rb complex was detected in the Caski cells. This was due to simultaneous accumulation of high level of E7 protein in the proteasome inhibitor treated cells. We further demonstrated that E7 is also regulated by ubiquitin dependent proteolysis in Caski cells. Finally, our results also revealed that the E7 oncoprotein of human papillomavirus actively regulates the level of Rb ubiquitination.
Previous results have shown that acute overexpression of E7 by the adenoviral and retroviral vectors induce proteolytic degradation of Rb. Results presented in this study now extend this observation to HPV-containing cervical carcinoma cells. Using the HPV transformed Caski cells; we demonstrated that Rb is proteolysed by the 26S proteasome in cervical carcinoma cells. The transforming activity of E7 is directly related to its ability to interact with Rb (Halbert et al., 1992; Hecks et al., 1992) . Our previous result showed that E7-induced proteolysis of Rb relates to the transformation function of E7 (Berezutskaya et al., 1997b) . Therefore, it is reasonable to suggest that targeted proteolysis of Rb by E7 is crucial for tumor formation in HPV-transformed epithelia.
In this study, we also provided evidence that Rb is modi®ed by ubiquitination. Previous studies have shown that Rb is degraded by 26S proteasome in cells over-expressing E7 (Boyer et al., 1996 , Berezutskaya et al., 1997b . Most proteins are multiubiquitinated prior to degradation by the 26S proteasome (reviewed in Hochstrasser 1996; King et al., 1996) . However, there are exceptions; for example, the ornithine decarboxylase is not multi-ubiquitinated prior to degradation by the 26S proteasome (Murakami et al., 1992) . Rb is modi®ed by phosphorylation and this modi®cation is critical for the growth suppression function of Rb (Chen et al., 1989; Weinberg, 1995) . Results presented in this study now demonstrate that Rb is also modi®ed by ubiquitination in cervical cancer cells. The tumor suppressor Rb is a critical regulator of the cell growth and dierentiation (reviewed in Lipinski and Jacks, 1999; Weinberg, 1995) . The function of the Rb protein is inactivated in a wide range of human cancers. In a subset of human cancers like retinoblastoma, small lung carcinomas, and bladder cancers, Rb is inactivated by`loss of function' mutations of the retinoblastoma gene. In another large group of tumors, the Rb protein is functionally inactivated by hyperphosphorylation following over-expression of cyclins or inactivation of cyclin-dependent kinase inhibitors. In human cervical cancers, the Rb gene is often wildtype, and results from this study and others now Past studies demonstrated that the E6 oncoprotein of HPV induces ubiquitination and degradation of the tumor suppressor p53 through the 26S proteasome (reviewed in Howley, 1996) . Thus, it appears that the papillomavirus oncoproteins depend heavily on the cellular 26S proteasome to carry out their oncogenic functions. However, there is a major dierence between E6-mediated degradation of p53 and E7-mediated degradation of Rb. The wild-type p53 protein has a short half-life (about 30 min) and it is ubiquitinated and degraded by the 26S proteasome in both non-HPV and HPV-transformed cells (Maki et al., 1996) . On the contrary, the Rb protein is not a major substrate of proteasomal degradation in absence of E7. In proliferating primary ®broblasts, in primary breast epithelial cells (Boyer et al., 1996) and in primary keratinocytes (Jones and Munger, 1997), the wild-type Rb protein has a long half-life, and only E7 expression can dramatically reduce the half-life of Rb in these cells. Taken together, these results showed that the proteasomal degradation of Rb by E7 is an inducible proteolytic event. E7 actively participates in the modi®cation of Rb, a stable tumor suppressor protein with long half-life to an unstable ubiquitinated form that has signi®cantly lower half-life. Our studies also showed that Rb mutants that are unable to bind E7 are not degraded by E7. The E7 protein binds only to the active hypophosphorylated form of Rb, which suggests that phosphorylated forms of Rb that cannot bind E7 are not the targets of the proteasomal degradation. Consistent with this notion, phosphorylated wild-type Rb are detected in majority of the HPV-transformed cervical carcinoma cells (reviewed in zur Hausen, 1999). and treated with MG132 (0.5 ± 5 mM) for 4 h, the cell lysates (300 mg) were analysed for the E7 protein by Western blot assay. (b) C33A cells were transfected with either an Rb-expressing plasmid (6 mg) alone or cotransfected with the Rb-(6 mg) and the E7-expressing (2.5 mg) plasmids. After 26 h of transfection, the cells were treated with either DMSO or MG132 (10 mM) for 4 h, and the cells lysates were analysed by Western blot assay for the Rb protein (top) and E7 protein (bottom). (c) C33A cells were transfected with either an Rb-expressing plasmid (10 mg) alone or cotransfected with the Rb-(10 mg) and the wild-type E7-(4 mg) or the C24-S mutant E7 (4 mg) or the E26-Q mutant E7 (4 mg) expressing plasmids. After 30 h of transfection, the cells lysates were analysed by Western blot assay for the Rb protein (top) and E7 protein (bottom). (d) C33A cells were transfected with either an Rb-expressing plasmid (10 mg) alone or cotransfected with the Rb expressing plasmid (10 mg) and the C24-S mutant E7 (4 mg) or the E26-Q mutant E7 (4 mg) expressing plasmid. After 26 h of transfection, the cells were treated with MG132 (10 mM) for 4 h, and the cells lysates were analysed by Western blot assay for the Rb protein (top) and E7 protein (bottom) In addition, the results presented in this study also revealed that the level of the E7 protein in cervical carcinoma cells is regulated by the 26S proteasome. We observed a 5 ± 8-fold increase in levels of the E7 protein in HPV-transformed Caski cells following treatment with the proteasome inhibitor MG132. We also showed accumulation of signi®cant level of polyubiquitinated E7 in MG132 treated Caski cervical carcinoma cells. Similarly, in cotransfection assays, when MG132 speci®cally blocked the proteolysis of Rb by E7, the levels of both Rb and E7 were increased. Since Rb is not a major target of 26S proteasome in absence of E7, it is likely that E7 recruits Rb for ubiquitination and proteasomal degradation. In support of this hypothesis, we show that E7 induces ubiquitination of Rb. The mechanism of the E7-induced ubiquitination of Rb is not elucidated from this study. It is possible that as in the case of E6-mediated degradation of p53, a dedicated E7-associated ubiquitin ligase like E6-AP is involved in E7-induced Rb ubiquitination. The detection of the Rb-speci®c ubiquitin ligase and the E7-speci®c ubiquitin ligase would help in understanding the molecular mechanism of E7 induced ubiquitination of Rb. Following ubiquitination, the multi-ubiquitinated protein is recognized by speci®c subunits of 26S proteasome.
The 19S subunit of 26S proteasome contains such recognition proteins (Baumeister et al., 1998; Pickart, 1997) . Our previous studies identi®ed an interaction between the S4-subunit of the 26S proteasome with E7, and the S4-ATPase is one such recognition protein in the 19S subunit (Berezutskaya and Bagchi, 1997a; Dubiel et al., 1992; Rechsteiner et al., 1993) . It is possible that S4 is involved in the ubiquitin dependent proteolysis of E7. It is also possible that S4 is involved in E7 induced ubiquitination and degradation of Rb.
Proteolysis of Rb is also relevant to the productive life cycle of the human papillomavirus, which replicates its genome in the dierentiated keratinocytes (Pan and Griep, 1994; Cheng et al., 1995) . Rb protein is involved in multiple stages of the dierentiation process, including permanent exit from the cell cycle and in maintenance of the post-mitotic state (reviewed in Lipinski and Jacks, 1999) . Rb is converted to the growth-arresting hypophosphorylated form in dierentiating keratinocytes and participates in blocking DNA replication in these cells (Chen et al., 1989; Ruesch and Laimins, 1998) . Previous studies have shown that the E7 protein alone is capable of reactivating cellular DNA replication in dierentiated epithelial cells (reviewed in Lamins, 1993, Pan and Griep, 1994; Cheng et al., 1995) . In a widely accepted model, E7 functionally inactivates Rb following a stoichiometric interaction with the hypophos-phorylated Rb. Results presented in this report show that Rb/E7 interaction leads to ubiquitination and degradation of Rb through the 26S proteasome. This result now provides the basis of reactivation of DNA synthesis by HPVs in dierentiated epithelia.
Materials and methods
Plasmids and reagents
The CMV-driven Rb-and the E7-expression plasmids have been described previously (Berezutskaya et al., 1997b) . The His 6 -tagged ubiquitin expression plasmid was generously provided by Dr Dirk Bohmann of Heidelberg, Germany (Musti et al., 1997) . To obtain the V5-epitope tagged Rb, the Rb cDNA sequences (encoding amino acids 379 ± 928) were recovered by polymerase chain reaction (PCR). GGG GAA TTC AGC AGG TAT GAT CCA ACA ATT AAT GAT GATT was used as the upstream primer and GGC CTC GAG TTT CTC TTC CTT GTT TGA GGT ATC CAT was used as the downstream primer. The PCR product was subcloned between the EcoRI and the XhoI site of the vector pcDNA3.1/V5-HisA (Invitrogen). The protease inhibitors, calpain inhibitor II, E64, and MG132 were from Sigma. The leupeptin, lactacystin, caspase-1 inhibitor (YVAD ± CHO), caspase-3 inhibitor (DEVD ± CHO), and proteasome-inhibitor I (PSI) were from Calbiochem.
Antibodies
The Rb monoclonal antibodies G3-245 and G99-549 were from PharMingen. The Rb monoclonal antibody (Ab-1, C36) , and hexahistidine (His 6 )-tagged ubiquitin (4 mg) were transfected in C33A cells. Twenty-six hour after transfection, the indicated transfected cells were treated with either DMSO or MG132 (10 mM) for 4 h, and the cells were harvested. Ubiquitin conjugates of V5-epitope tagged Rb were puri®ed from the transfected cell lysates (3 mg) by immunoprecipitation with V5 monoclonal antibody and were analysed by 8% polyacrylamide-SDS gel and were detected by protein immunoblotting with antiHis antibody. (b) The same transfected cell lysates (400 mg) were probed with the V5-antibody to determine the level of V5-epitope tagged Rb in the transfected cell extract conjugated to the agarose beads was from Oncogene Science. The Rb polyclonal antibody against the C-terminal peptide (C-15), the p107 polyclonal antibody (C-18), the p130 polyclonal antibody (C-20), the anti-His antibody (H-15), and the Ub monoclonal antibody (P1A6) were from Santa Cruz Biotechnology. The E7 monoclonal antibody (ED17), and the E7 monoclonal antibody (TVG710Y) conjugated with agarose beads were from Santa Cruz Biotechnology. The V5-monoclonal antibody was from Invitrogen.
Cell culture and transfection
Caski and C33A cells were obtained from the American Type Culture Collection. C33A cells were grown in DMEM (GIBCO ± BRL) supplemented with 10% fetal bovine serum. Caski cells were grown in RPMI supplemented with 10% fetal bovine serum. C33A cells were transfected at 60% con¯uence, using the calcium phosphate co-precipitation method as described previously (Berezutskaya et al., 1997b) . DNA precipitates were removed 12 h after transfection and the cells were replenished with fresh medium. Cells were harvested after 30 h, and the cell lysates were prepared using extraction buer containing 20 mM HEPES (pH 7.9), 0.1% NP40, 0.4 M NaCl, 1 mM EDTA, 2.5 mM dithiothreitol, 5 mM NaF, 20% glycerol and 1 ug each of aprotinin, leupeptin, and pepstatin per ml and 0.5 mM phenylmethylsulphonyl¯uoride. One microgram of CMV-b-galactosidase plasmid was also cotransfected to monitor the transfection eciency. Approximately 26 h after the transfection, the cells were treated with either DMSO or the protease inhibitors for 4 h prior to harvesting. For the actinomycin-D treatment, the Caski cells were treated for 4 h with 2.4 nM actinomycin-D, washed twice with complete medium and were incubated for another 24 h in complete medium.
SDS ± PAGE, Western blot, and immunoprecipitation
The cell lysates made from transient transfection assays were normalized against the b-galactosidase and were subjected to immunoprecipitation assay following standard procedures (Berezutskaya et al., 1997b) . For detection of the Rbubiquitin conjugates, cells were treated with either DMSO or MG132 (10 mM) for 4 h, and cell extracts were made in the lysis buer containing 50 mM Tris (pH 7.5), 5 mM EDTA, 150 mM NaCl, 0.1% SDS, 0.6% NP40, 1 mM PMSF for 30 min at 48C. Three-milligrams protein from each cell extract was immunoprecipitated using the agarose conjugated Rb-monoclonal antibody (Rb-Ab1). The immunoprecipitates were resolved by SDS-polyacrylamide gel electrophoresis, and probed with the monoclonal ubiquitin antibody using the Western blot assay. For detection of the E7-ubiquitin conjugates, the same Caski cell lysates were immunoprecipitated with agarose conjugated monoclonal E7 antibody and the immunoprecipitates were probed with monoclonal ubiquitin antibody using the Western blot assay.
E2F binding assay
E2Fs in the Caski cell extract were assayed on the basis of their ability to bind DNA in a sequence-speci®c manner. The condition of the assay has been described elsewhere (Raychaudhuri et al., 1991) . For the antibody supershift assays, 5 mg of Caski cell extract was mixed with 1 ml of the respective antibody prior to the gel retardation assay.
